Lupus Therapeutics Partners to Evaluate Potential Treatment for SLE and Lupus Nephritis Through North American Trial Network

NEW YORK, NY, June 2, 2023 — Lupus Research Alliance clinical research affiliate Lupus Therapeutics will collaborate with Novartis Pharmaceuticals Corporation to conduct  three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis through the Lupus Clinical Investigators Network (LuCIN) at top academic centers throughout North America.

The full press release is available on the Lupus Therapeutics website.

Read full Press Release

Recent Press Releases

Press Release
The RRF and LRA Join Forces to Offer Funding to Address Lupus
The Rheumatology Research Foundation and the Lupus Research Alliance Join Forces to Offer Funding to Address Lupus
Amid ongoing fluctuations in federal research funding, a declining physician workforce, and increasing patient needs, the Rheumatology Research Foundation...
Press Release
2024 Awardees: Lupus Innovation Award
Lupus Research Alliance Grants Lupus Innovation Awards to Eleven Talented Researchers to Accelerate Pace of Discovery in Lupus Research
April 15, 2025
The Lupus Research Alliance (LRA) is proud to announce the recipients of this year’s Lupus Innovation Award (LIA), addressing...
Press Release
2025 Targeted Research Program on Engineered Cell Therapies for Lupus (TRP-ECT) Awardees
Lupus Research Alliance Grants Inaugural Awards to 11 Researchers Focused on Engineered Cell Therapies for Lupus
March 20, 2025
The Lupus Research Alliance (LRA) is proud to announce the inaugural recipients of the new Targeted Research Program on...